- Home
- PHVS vs AVNS Comparison
PHVS vs AVNS Comparison
Compare PHVS & AVNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- AVNS
- Stock Information
- Founded
- PHVS 2015
- AVNS 2014
- Country
- PHVS Netherlands
- AVNS United States
- Employees
- PHVS N/A
- AVNS N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- AVNS Industrial Specialties
- Sector
- PHVS Health Care
- AVNS Health Care
- Exchange
- PHVS Nasdaq
- AVNS Nasdaq
- Market Cap
- PHVS 1.0B
- AVNS 731.6M
- IPO Year
- PHVS 2021
- AVNS N/A
- Fundamental
- Price
- PHVS $18.86
- AVNS $15.88
- Analyst Decision
- PHVS Strong Buy
- AVNS Hold
- Analyst Count
- PHVS 5
- AVNS 1
- Target Price
- PHVS $40.60
- AVNS N/A
- AVG Volume (30 Days)
- PHVS 73.1K
- AVNS 362.1K
- Earning Date
- PHVS 11-13-2024
- AVNS 02-18-2025
- Dividend Yield
- PHVS N/A
- AVNS N/A
- EPS Growth
- PHVS N/A
- AVNS N/A
- EPS
- PHVS N/A
- AVNS 0.34
- Revenue
- PHVS N/A
- AVNS $681,500,000.00
- Revenue This Year
- PHVS N/A
- AVNS $3.84
- Revenue Next Year
- PHVS N/A
- AVNS $4.37
- P/E Ratio
- PHVS N/A
- AVNS $33.80
- Revenue Growth
- PHVS N/A
- AVNS N/A
- 52 Week Low
- PHVS $15.37
- AVNS $15.51
- 52 Week High
- PHVS $33.00
- AVNS $25.36
- Technical
- Relative Strength Index (RSI)
- PHVS 51.83
- AVNS 34.17
- Support Level
- PHVS $18.18
- AVNS $15.51
- Resistance Level
- PHVS $19.88
- AVNS $16.29
- Average True Range (ATR)
- PHVS 1.11
- AVNS 0.49
- MACD
- PHVS 0.17
- AVNS -0.03
- Stochastic Oscillator
- PHVS 76.86
- AVNS 19.94
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About AVNS Avanos Medical Inc.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.